Sephure, the first of its kind patented disposable suppository applicator

July 20, 2014
00:0000:00


Jennifer Davagian Ensign, CEO of Cristcot, Inc. and inventor of Sephure, the first-of-its kind patented disposable suppository applicator that provides a more comfortable and hygienic way to administer suppository medication joins eHealth Radio and the Health and News Channels.


Duration: 10:30


Listen to interview with host Eric Michaels and guest Jennifer Davagian Ensign discuss the following:

  • What is Sephure, and why did you invent it?
  • Who is this product designed for?
  • What obstacles did you run into during the inventing/manufacturing process?
  • You launched the product on April 1st of this year and have already been to one of the industry’s largest trade shows – Digestive Disease Week.  What has the reaction been from the medical community?
  • How can one order Sephure?


Jennifer Davagian Ensign is the founder and CEO of Cristcot, a medical device company, located in Concord, Massachusetts. Funded in part by the Massachusetts Life Sciences Center, Cristcot was named one of the five most promising emerging life science companies in the Commonwealth for 2012.


In 2014, Cristcot launched Sephure, the first-of-its-kind disposable suppository applicator. The device, invented by Ensign, has FDA clearance, global patent protection, and is manufactured in the United States in an ISO-13485 facility and is distributed worldwide.


As a Crohn’s patient, Ensign knows the daily struggles of IBD patients and compliance decisions facing healthcare outcomes. As a businesswoman in the area of Science, Technology and Manufacturing, she has a keen understanding of new medical technology development and product life cycle. Ensign has given talks on topics of patient compliance, intellectual property development and commercialization cycles of new medical technologies.


Most notably, Jennifer gave a keynote address at the 2013 International Conference of Gastroenterology.  As a thought leader in the area of topical rectal medication treatment for gastrointestinal disease, she has written for both the National Institute of Health and the Food and Drug Administration.



Web Site: www.sephure.com
Facebook: www.facebook.com/SephureUSA
Twitter: @Sephure